Article details
Middle East Pharmaceutical Industries Co. (Avalon Pharma) shareholders will vote on a 75% capital increase via a 3-for-4 bonus share issue on May 11. The company’s current capital stands at SAR 200 million with 20 million shares outstanding. The proposed increase will raise capital to SAR 350 million by capitalizing SAR 150 million from retained earnings. The move aims to strengthen the company’s financial position, support growth strategies, and enhance returns for shareholders.
This capital restructuring is a non-dilutive way to boost liquidity and expand operations. For traders, the bonus issue will increase the share count but not the company’s market value, potentially diluting earnings per share in the short term. However, the long-term impact depends on how effectively the additional capital is deployed. Investors should monitor the shareholder vote outcome and any subsequent changes in the stock’s valuation metrics.
For Saudi equity markets, this development highlights active capital management among listed firms. MENA investors should assess Avalon Pharma’s post-announcement performance and watch for technical signals like support/resistance levels around key price points. The broader market may react if similar capital increases gain traction in the sector.
